These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36106755)

  • 1. Medication-related osteonecrosis of the jaw: A literature review and update.
    Kuroshima S; Al-Omari FA; Sasaki M; Sawase T
    Genesis; 2022 Sep; 60(8-9):e23500. PubMed ID: 36106755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M; Kuroshima S; Sawase T
    Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging antiresorptive medications and their potential implications for dental surgeries.
    Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
    J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
    Halpern LR; Adams DR
    Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
    Adachi N; Ayukawa Y; Yasunami N; Furuhashi A; Imai M; Sanda K; Atsuta I; Koyano K
    Sci Rep; 2020 Mar; 10(1):5620. PubMed ID: 32221325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
    Bassan Marinho Maciel G; Marinho Maciel R; Linhares Ferrazzo K; Cademartori Danesi C
    J Mol Med (Berl); 2024 Mar; 102(3):353-364. PubMed ID: 38302741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
    Roato I; Mauceri R; Notaro V; Genova T; Fusco V; Mussano F
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
    Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
    Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
    Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab-related osteonecrosis of the jaw: a report of 2 cases and review of the literature.
    Chehal H; Nikitakis NG; Islam MN; Goodchild JH; Mordini L; Bhattacharyya I
    Gen Dent; 2019; 67(1):42-46. PubMed ID: 30644830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.
    Yarom N; Van Poznak CH; Epstein JB; Ottaviani G; Matsuda Y; Migliorati C; Elad S
    Support Care Cancer; 2024 Jul; 32(8):547. PubMed ID: 39048887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.